Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SSGJ-707 |
| Trade Name | |
| Synonyms | PF-08634404|SSGJ 707|SSGJ707|PF08634404|PF 08634404 |
| Drug Descriptions |
SSGJ-707 (PF-08634404) is a bispecific antibody that targets PDCD1 (PD-1) and VEGF, which potentially decreases tumor growth (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_3). |
| DrugClasses | PD-L1/PD-1 antibody 136 VEGF Antibody 17 |
| CAS Registry Number | NA |
| NCIT ID | C223904 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + Nab-paclitaxel + SSGJ-707 | Carboplatin Nab-paclitaxel SSGJ-707 | 0 | 0 |
| Carboplatin + Paclitaxel + SSGJ-707 | Carboplatin Paclitaxel SSGJ-707 | 0 | 0 |
| Carboplatin + Pemetrexed Disodium + SSGJ-707 | Carboplatin Pemetrexed Disodium SSGJ-707 | 0 | 0 |
| SSGJ-707 | SSGJ-707 | 0 | 3 |